초록 ▼

Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic aci

Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy.

대표청구항 ▼

1. A composition comprising: (a) an intact, bacterially derived minicell that comprises (i) a functional nucleic acid molecule or (ii) a plasmid comprising a segment that encodes a functional nucleic acid molecule, wherein the functional nucleic acid molecule targets the transcript of a protein that

1. A composition comprising: (a) an intact, bacterially derived minicell that comprises (i) a functional nucleic acid molecule or (ii) a plasmid comprising a segment that encodes a functional nucleic acid molecule, wherein the functional nucleic acid molecule targets the transcript of a protein that contributes to apoptosis resistance or resistance to a chemotherapeutic drug, and wherein the functional nucleic acid is an shRNA, shRNA, or miRNA, and(b) a pharmaceutically acceptable carrier therefore, andwherein upon administration the minicell is engulfed by a mammalian cell and releases the functional nucleic acid into the cytoplasm of the cell. 2. The composition of claim 1, wherein the plasmid comprises a regulatory element operably linked to the segment that encodes a functional nucleic acid. 3. The composition of claim 2, wherein the regulatory element is a promoter dependent on RNA polymerase. 4. The composition of claim 3, wherein the promoter is the RNA polymerase III promoter H1 or U6 or 7SK or the RNA polymerase II promoter CMV immediate early promoter. 5. The composition of claim 1, wherein the functional nucleic acid molecule targets the transcript of P-glycoprotein, MDR-2 or MDR-3. 6. The composition of claim 1, wherein the functional nucleic acid molecule targets the transcript of MRP2, BCR-ABL, STI-571 resistance-associated protein, lung resistance-related protein, cyclooxygenase-2, nuclear factor kappa, XRCC1, ERCC1, GSTP1, mutant β-tubulin, or a growth factor. 7. The composition of claim 1, wherein the functional nucleic acid molecule targets the transcript of a protein that contributes to apoptosis resistance. 8. The composition of claim 7, wherein the functional nucleic acid molecule targets a transcript of Bcl-2, Bcl-XL, A1/Bfl 1, focal adhesion kinase or p53 protein. 9. The composition of claim 1, wherein the functional nucleic acid molecule targets a transcript of a protein that contributes to neoplasticity. 10. The composition of claim 9, wherein the functional nucleic acid molecule targets a transcript of β-Catenin, PKC-α, C-RAF, K-Ras, DP97 Dead box RNA helicase, DNMT1, FLIP, C-Sfc, 53BPI, Polycomb group protein EZH2, ErbB1, HPV-16 E5 and E7, Fortilin & MCI1P, DIP13α, MBD2, p21, KLF4, tpt/TCTP, SPK1 & SPK2, P300, PLK1, Trp53, Ras, ErbB1, VEGF, or BAG-1. 11. The composition of claim 1, wherein the plasmid encodes multiple functional nucleic acid molecules. 12. The composition of claim 11, wherein the plasmid further comprises a promoter for each encoded functional nucleic acid molecule. 13. The composition of claim 1, further comprising a drug. 14. The composition of claim 1, further comprising a bispecific ligand. 15. The composition of claim 14, wherein the bispecific ligand comprises a first arm that carries specificity for a minicell surface structure and a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor. 16. The composition of claim 15, wherein the minicell surface structure is an O-polysaccharide component of a lipopolysaccharide on the minicell surface. 17. The composition of claim 15, wherein the mammalian cell surface receptor is capable of activating receptor-mediated endocytosis of the minicell. 18. The composition of claim 14, wherein the bispecific ligand comprises an antibody or antibody fragment. 19. The composition of claim 1, wherein the composition contains fewer than about 1 contaminating parent bacterial cell per 107 minicells. 20. The composition of claim 1, wherein the composition contains fewer than about 1 contaminating parent bacterial cell per 108 minicells. 21. The composition of claim 1, wherein the composition contains fewer than about 1 contaminating parent bacterial cell per 109 minicells. 22. The composition of claim 1, wherein the composition contains fewer than about 1 contaminating parent bacterial cell per 1010 minicells. 23. The composition of claim 1, wherein the composition contains fewer than about 1 contaminating parent bacterial cell per 1011 minicells.